The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Long-term follow up (FU) of patients with durable complete response (DCR) after chemotherapy (CT) and HER2-targeting systemic therapy (HER2-Tx) for HER2+ metastatic breast cancer (MBC).
Giuseppe Gullo
No relevant relationships to disclose
Annamaria De Giorgi
No relevant relationships to disclose
Cecily Quinn
No relevant relationships to disclose
Jo Ballot
No relevant relationships to disclose
Lisa Hammond
No relevant relationships to disclose
John Crown
No relevant relationships to disclose